Hims & Hers Faces A 'Transition Year' Amid Increasing AI Investments, Says KeyBanc – Expects Lower Pricing To Weigh On FY2027-2028 Earnings Outlook

What happened

KeyBanc said 2026 could be a transition year for Hims & Hers as it invests in artificial intelligence, new treatments and international expansion. It said lower treatment prices may eventually attract subscribers and increase treatments per customer, but could weigh on 2027 and 2028 revenue and adjusted EBITDA forecasts.

Confirmed

Global impact / market context

Lower prices could bring in more subscribers and encourage existing customers to use more treatments, potentially supporting sales over time. Before those gains arrive, however, reduced prices and spending on new initiatives could pressure revenue and adjusted EBITDA, a measure of operating earnings, in 2027 and 2028.

Analyst inference

The article reports a 49% year-over-year rise in third-quarter revenue to $890.4 million, alongside a $33 million net loss. Subscribers grew 13% year over year but fell from 2.89 million in the prior quarter to 2.79 million, partly as marketing spending declined.

Confirmed

What to watch

1. Look for evidence that lower treatment prices bring in subscribers or increase treatments per customer; KeyBanc said it is still too early to judge whether those benefits will emerge. Analyst inference
2. Track whether the planned investment in artificial intelligence, new treatments and international expansion is followed by stronger revenue, while distinguishing near-term costs from later gains. Analyst inference
3. Watch for updated 2027 and 2028 revenue and adjusted EBITDA forecasts, since KeyBanc warned these outlooks could be weighed down by the initiatives and lower pricing. Confirmed

Evidence

• stocktwits.com